PCSK9 List Price Discounts Of 67% To 85% Suggested By ICER Analysis
Methods and conclusions for group’s report on the value and optimal pricing for Repatha and Praluent draw criticism from drug industry stakeholders, some policy experts. Approach includes cost-effectiveness review, novel US budget impact analysis.
You may also be interested in...
The Institute for Clinical & Economic Review is setting an appropriately broad scope in its review of the abuse-deterrent opioid class. But the project opens up a much larger question of how broadly to define value – and how to weigh non-economic values – in cost-effectiveness reviews.
Analysis published in the Journal of the American Medical Association is the latest to argue that PCSK9 inhibitors are not cost-effective.
Institute for Clinical and Economic Review plans to unveil an updated drug value framework in early 2017.